Abbey Jenkins, Gamida Cell CEO
March 27, 2023 11:21 AM EDTUpdated 12:31 PM
People
R&D

Gami­da Cell makes more staff cuts and re­struc­tures as it fo­cus­es on po­ten­tial drug launch

Tyler Patchen

News Reporter

Gami­da Cell is mak­ing some re­struc­tur­ing moves as it pre­pares for the po­ten­tial ap­proval of its lead drug.

In Gami­da Cell’s 2022 year-end

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times